



Implementation of HPV testing across Africa: Practical partnering and experience sharing to help achieve the WHO 2030 cervical cancer elimination targets

ASLM2021 Satellite Session

Sponsor

Roche Diagnostics

Date and Time

18 November 2021, 8AM-9AM GMT

Summary

Cervical cancer affects hundreds of thousands of women each year across Africa. HPV DNA testing has been shown to be the most effective secondary prevention tool in the fight against cervical cancer. With the WHO 2030 global elimination strategy, supported by the World Health Assembly of 194 countries, the opportunity is now to plan, implement and expand effective, life-saving cervical cancer screening programs.

During this symposium information will be shared and discussed to help with implementation of HPV DNA testing within cervical cancer programs with an emphasis on the laboratory perspective. This includes sharing from country experiences on how to transition from VIA to HPV DNA testing and the challenges and opportunities to integrate HPV DNA testing with HIV programs.

Learning Objectives

- To support countries in strengthening their capacity to reach the WHO 2030 cervical cancer goal for HPV DNA testing
- To provide practical information on how to overcome challenges and to implement, scale-up and successfully sustain HPV testing across Africa as part of secondary cervical cancer prevention strategies
- To highlight the importance of the laboratory and value of diagnostics for HPV screening programs

Target Audience

Laboratory professionals, implementing partners, technical working group members, cervical cancer program managers.